Novo Nordisk's Oral Wegovy Clears a Chinese Hurdle While the Bearish Case Hardens

China accepts oral Wegovy filing, but Novo Nordisk faces pipeline setbacks and Lilly competition, with stock down 28% from peak.

The acceptance of a regulatory filing rarely moves a stock. But when China's drug authority agreed this week to review Novo Nordisk's oral Wegovy application, it landed at a moment when the Danish pharma giant is fighting on two fronts at once: defending its GLP-1 franchise against an emboldened Eli Lilly while trying to convince investors that its pipeline extends beyond the injectable blockbusters that built its fortune.

The market's initial response was telling. Shares slipped 2.8 percent on Thursday to 39.47 euros, extending a slide that has left the stock roughly 28 percent below its late-January peak. The muted reaction underscores just how much skepticism has accumulated around Novo Nordisk's growth narrative — and how one regulatory milestone, however significant, may not be enough to reverse it.

A Pipeline Setback That Changed the Calculus

The bearish case hardened considerably on August 27, when Deutsche Bank analyst Emmanuel Papadakis cut Novo Nordisk to "Sell" from "Hold" and trimmed the price target by 9 percent to 265 Danish kroner. The trigger: late-stage cardiovascular data showing Ziltivekimab failed to reduce the risk of heart attack or stroke. The drug was supposed to be a cornerstone of Novo's diversification beyond Wegovy and Ozempic — now its central efficacy proof has come up short.

The stock fell 2.3 percent that day to close at 39.65 euros, leaving it below its 50-day moving average of 41.80 euros. Two weeks earlier, Berenberg had already pulled its rating down from "Buy" to "Hold". The clustering of negative analyst actions in quick succession points to a pattern that extends beyond any single trading session.

The setback was not entirely out of the blue. Novo Nordisk had already trimmed its 2026 guidance, now calling for adjusted revenue growth of between 0 and minus 6 percent at constant exchange rates, with operating profit expected to move in the same range. Second-quarter results included non-recurring impairments of 6.3 billion kroner, of which 4.0 billion were tied to Monlunabant — evidence that the pipeline was under strain before the Ziltivekimab disappointment landed.

The Chinese Opening and the Pill Strategy

Against that backdrop, the Chinese acceptance carries real strategic weight. It marks the clearest signal yet that Novo Nordisk intends to compete in the oral weight-loss market at scale — and that it sees China, with its hundreds of millions of potential patients, as a decisive battleground.

CEO Mike Doustdar has been explicit in recent weeks that the race with Eli Lilly is not a winner-take-all contest. The company is betting that a broader pipeline and market access will ultimately matter more than any single molecule debate. The China filing is precisely the kind of building block Doustdar was referring to.

The oral Wegovy push has been accelerating on multiple fronts: the pill's launch in Germany, the start of the OASIS-5 late-stage study testing lower maintenance doses in 450 overweight adults without diabetes over 60 weeks, and now the Chinese filing. Since its January launch, the Wegovy pill has surpassed 5 million prescriptions, according to Doustdar — a figure that suggests patient demand remains robust even as pricing pressure intensifies.

Competition Heats Up on Multiple Fronts

Eli Lilly, meanwhile, keeps gaining ground. The rival secured its first approval for the weight-loss drug Foundayo in the United Kingdom in mid-August, just two months after Novo introduced its Wegovy pill there. If Lilly consolidates its lead in oral GLP-1 treatments across Europe while Novo grapples with pipeline setbacks, the valuation pressure could persist.

The US market adds another layer of concern. Novo has warned of declining US sales, citing intensifying competition and reduced Medicaid coverage for obesity medications. The Wegovy pill's second-quarter sales of 3.22 billion kroner came in just shy of the 3.27 billion kroner analysts had expected — a small miss, but one that feeds the narrative of a company losing momentum where it matters most.

Buybacks, Partnerships, and a Production Snag

Management has signaled confidence through its buyback program: nearly 30 million B-shares repurchased as of August 21, with up to 11.2 billion kroner in additional buyback capacity running until early February 2027. The company's market capitalization stands at roughly 180.55 billion euros.

Novo is also spreading bets across the obesity ecosystem. Lexicon Pharmaceuticals received a third milestone payment of $10 million on Monday after reaching a key dosing step in the Phase 1 program for LX9851. A separate collaboration with Novonesis explores microbiome-based products as complements to GLP-1 therapies, though results are not expected until the second half of 2027.

Not every piece of news has been positive. Scholar Rock withdrew its European filing for a spinal muscular atrophy treatment last week, citing manufacturing issues at a Novo Nordisk facility in Bloomington, Indiana, and plans to use a different production site going forward. The episode is a reminder that Novo's role as a contract manufacturer for third parties carries its own risks.

What Happens Next

The technical picture offers some room for interpretation. The stock sits just 1.4 percent below its 200-day moving average of 40.21 euros — as long as that level holds, the chart-based support structure remains intact. A sustained break below it, however, could invite another round of price-target cuts from the analyst community.

The relative strength index at 44.4 suggests the stock is not deeply oversold, leaving space for a technical stabilization. But the fundamental questions are more pressing: Can prescription growth for the oral Wegovy hold up in the coming months? Will further pipeline data confirm or dispel doubts about the diversification strategy?

The next concrete test comes with the quarterly results, which will show whether the company's 0-to-minus-6 percent growth guidance lands at the upper or lower end. For now, Novo Nordisk is working on many fronts simultaneously — the question is whether that breadth of effort translates into a narrowing of the gap with Eli Lilly, or merely a holding action.